Occam Places Lisa Deschamps as CEO of AviadoBio
Occam recently recruited Lisa Deschamps to AviadoBio. She takes the helm of this neuro gene therapy company based on the scientific research of Chris Shaw of King’s College London after having had a distinguished career at Novartis in a variety of senior executive management positions in neuroscience and gene therapy. In addition to bringing deep content knowledge to Aviado, Lisa has also provided leadership for the company’s recently successful $80 million financing, bringing in new investors including NEA.
Occam Global is a biotech executive search, recruiting, and leadership advisory firm with specialties across technological fields, including Biotech, TechBio, AI-ML, Cell/Gene Therapy, Diagnostics/Genomics, Medical Devices, Research Tools, Digital Health, Alternative Energy, AgTech, EdTech, Robotics as well as adjacencies within Venture Capital and Private Equity. Occam helps build biotech executive leadership teams that meet the demands of the rapidly developing, competitive, and challenging industries it serves. Occam Global recruits leading C-Suite executives and board members for the most exciting and innovative clients across the world with a specific focus on the UK, Continental Europe, the US, and Asia.